Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938137 | 0.81 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL15156210 | 0.75 | HCAR2 (0.41) | HCAR2KEAP1NFE2L2RAB9A | |
| SCHEMBL14617834 | 0.75 | HCAR2 (0.41) | HCAR2KEAP1NFE2L2RAB9A | |
| SCHEMBL938157 | 0.73 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2ALDH1A1HPGD | |
| SCHEMBL2132535 | 0.73 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2ALDH1A1HPGD | |
| SCHEMBL15709423 | 0.73 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2RAB9AGFPT1 | |
| SCHEMBL15709422 | 0.73 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2RAB9AGFPT1 | |
| Hydrochloric Acid SCHEMBL2134245 | 0.71 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL2134248 | 0.71 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2ALDH1A1HPGD | |
| SCHEMBL30301080 | 0.71 | HCAR2 (0.34) | HCAR2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | HCAR2 3748/4885KEAP1 1402/4885NFE2L2 1001/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | HCAR2 3748/4885KEAP1 1402/4885NFE2L2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.